GSK has halted all shipments of ARIXTRA Starter Kits containing the Triad For important product information, log onto Arixtra mg/ ml solution for injection, pre-filled syringe. 2. .. Detailed information on this medicinal product is available on the website of the European . Arixtra is a medicine that helps prevent blood clots from forming in the blood This medicinal product contains less than 23 mg of sodium in each dose and.
|Published (Last):||12 May 2010|
|PDF File Size:||4.76 Mb|
|ePub File Size:||6.68 Mb|
|Price:||Free* [*Free Regsitration Required]|
Subscribe to receive email notifications whenever new articles are published.
When selecting an appropriate thromboprophylaxis regimen, consider factors such as relative efficacy, bleeding risk, logistics, and compliance issues. Evaluate the possibility of an underlying bleeding disorder before initiation of treatment. Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: Prevention of VTE in nonsurgical patients: Patients should be sitting or supine during administration.
Insert the entire length of the needle into pescribing skin fold created by the thumb and forefinger; hold the skin fold, and push the plunger of the syringe the full length of the syringe barrel. Anticoagulant effects may persist for 2—4 days following discontinuance of therapy in patients with normal renal function i. Discontinue oral anticoagulants prior to initiation of fondaparinux 1 40 If coadministration is essential, monitor patients closely 1 Extended thromboprophylaxis for up to 35 days is recommended in patients undergoing hip fracture surgery, 40 and suggested for patients undergoing other major orthopedic procedures.
To view content sources and attributions, please refer to our editorial policy. Latex-containing devices; user labeling. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. A predcribing double-blind trial.
Patients undergoing abdominal surgery: Active major bleeding, bacterial endocarditis, or thrombocytopenia associated with a positive in vitro test for antiplatelet antibody HIT in the presence of the drug.
ACCP recommends fondaparinux as an option for thromboprophylaxis in acutely ill, hospitalized medical patients at increased informaton of thrombosis.
If coadministration is essential, monitor patients closely 1 Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs.
We comply with the HONcode standard for trustworthy health information – verify here. Used for extended prophylaxis i. J Am Coll Cardiol. Importance of discontinuing fondaparinux and immediately contacting a clinician if a serious allergic reaction e.
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Postoperative wound infection, postoperative hemorrhage, fever, surgical site reaction, anemia, hypertension, pneumonia, vomiting.
History of serious hypersensitivity reaction e.
Arixtra Monograph for Professionals –
Usual duration of therapy is 5—9 days, although up to 10 days has been studied. In general, pharmacologic thromboprophylaxis is recommended only in such patients considered to be at high risk of venous thromboembolism. Dosages for fondaparinux sodium and heparin, heparinoids, or LMWHs cannot be used interchangeably on a unit-for-unit or mg-for-mg basis 1 as they differ in the manufacturing process, anti-factor Xa and antithrombin activity, and dosage. The activity of fondaparinux sodium is measured based on plasma drug concentrations quantified by anti-factor Xa activity using fondaparinux as the calibrator.
If pharmacologic prophylaxis is indicated in patients undergoing general surgery, ACCP states that an LMWH or low-dose heparin is preferred; fondaparinux may be considered when both an LMWH and heparin are contraindicated or not available.
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: Discontinue oral anticoagulants prior to initiation of fondaparinux 1 The easiest way to lookup drug information, identify pills, check interactions and inofrmation up your own personal medication records.
inforamtion Increased risk of hemorrhage; closely monitor for signs and symptoms of bleeding. Antithrombotic therapy for VTE disease: Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: Anticoagulation results from rapid inhibition of factor Xa by antithrombin III bound to fondaparinux about fold greater than innate activity.
Periodic routine blood counts, including platelet counts, and tests for occult blood in stool recommended. If coadministration is essential, monitor patients closely Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
Available for Android and iOS devices. Hull R, Pineo G. A randomized double-blind comparison. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip- fracture surgery.
Prevention of VTE in orthopedic surgery patients: Importance of informing patients of other important precautionary information. Prevention of VTE in nonorthopedic surgical patients: Arixtra Rating 5 User Reviews 8. Some packaging components e. Has been administered at an initial dose of 2.
Informagion clicking Subscribe, I agree to the Drugs. Am J Health-Syst Pharm.
Patients undergoing hip-fracture, hip- or knee-replacement surgery: N Engl J Med. Used in conjunction with warfarin for treatment of DVT and acute PE when initial therapy is administered in the hospital. Anemia, fever, nausea, edema, constipation, rash, vomiting, insomnia, increased wound drainage, hypokalemia, urinary tract infection, dizziness, purpura, hypotension, confusion, bullous eruption, urinary retention, hematoma, major bleeding, diarrhea, dyspepsia, postoperative hemorrhage, headache.